Linezolid dampens neutrophil-mediated inflammation in methicillin-resistant staphylococcus aureus-induced pneumonia and protects the lung of associated damages

Journal of Infectious Diseases

Volumn 210, Issue 5, 2014, Pages 814-823

  Jacqueline, Cédric ^a   Broquet, Alexis ^a   Roquilly, Antoine ^a   Davieau, Marion ^a   Caillon, Jocelyne ^a   Altare, Frédéric ^b   Potel, Gilles ^a   Asehnoune, Karim ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b CNRS   (France)

Author keywords

Animal model; Cytokines; Glycopeptides; Myeloperoxidase; Neutrophil; Oxazolidinones; Pneumonia; Staphylococcus aureus

Indexed keywords

INTERLEUKIN 1BETA; LINEZOLID; MACROPHAGE INFLAMMATORY PROTEIN 2; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG ENDOTHELIAL PERMEABILITY; LUNG ENDOTHELIUM; LUNG LESION; LUNG PROTECTION; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL MEDIATED INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ANIMAL MODEL; CYTOKINES; GLYCOPEPTIDES; MYELOPEROXIDASE; NEUTROPHIL; OXAZOLIDINONES; PNEUMONIA; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, LY; BACTERIAL LOAD; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; LUNG; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; NEUTROPHILS; OXAZOLIDINONES; PEROXIDASE; PNEUMONIA, STAPHYLOCOCCAL; VANCOMYCIN;

EID: 84907377983     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu145     Document Type: Article

References (47)

1. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51:3397-400.
2. Fowler VG Jr, Boucher HW, Corey GR, et al; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
3. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50.
4. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358:716-27.
5. Wong SS, Ng TK, Yam WC, et al. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 2000; 36:261-8.
6. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309:559-69.
7. Aoki H, Ke L, Poppe SM, et al. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002; 46:1080-5.
8. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40:799-801.
9. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004; 38:864-70.
10. Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun 2009; 77:568-75.
11. Mizgerd JP. Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Semin Immunol 2002; 14:123-32.
12. Anas AA, Wiersinga WJ, de Vos AF, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010; 68:147-52.
13. Kovaleva A, Remmelts HH, Rijkers GT, Hoepelman AI, Biesma DH, Oosterheert JJ. Immunomodulatory effects of macrolides during community- acquired pneumonia: a literature review. J Antimicrob Chemother 2012; 67:530-40.
14. Otto MP, Martin E, Badiou C, et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by communityacquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2013; 68:1524-32.
15. Diep BA, Afasizheva A, Le HN, et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 2013; 208:75-82.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 8th ed. Wayne, PA: CLSI, 2008.
17. Pearson RD, Steigbigel RT, Davis HT, Chapmann SW. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 1980; 18:699-708.
18. Burkhardt O, Borner K, von der Höh N, et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002; 50:707-12.
19. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin- resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 2008; 52:2156-62.
20. Peng GW, Stryd RP, Murata S, et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999; 20:65-73.
21. Roquilly A, Gautreau L, Segain JP, et al. CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia. PLoS One 2010; 5:e13228.
22. Roquilly A, Broquet A, Jacqueline C, et al. TLR-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur Respir J 2013; 42:1365-78.
23. Boutoille D, Marechal X, Pichenot M, Chemani C, Guery B, Faure K. FITC albumin as a marker for assessment of endothelial permeability in mice: comparison with 125I-albumin. Exp Lung Res 2009; 35:263-71.
24. Chapman AL, Hampton MB, Senthilmohan R, Winterbourn CC, Kettle AJ. Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of Staphylococcus aureus. J Biol Chem 2002; 277:9757-62.
25. Mizgerd JP, Skerrett SJ. Animals models of human pneumonia. Am J Physiol Lung Cell Mol Physiol 2008; 294:387-98.
26. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 2009; 34:1148-58.
27. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20.
28. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
29. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
30. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin- resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
31. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
32. Akinnusi ME, Hattemer A, Gao W, El-Solh AA. Does linezolid modulate lung innate immunity in a murine model of methicillin-resistant Staphylococcus aureus pneumonia? Crit Care Med 2011; 39:1944-52.
33. Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, et al. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2012; 67:1961-7.
34. Martinez-Olondris P, Rigol M, Soy D, et al. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med 2012; 40:162-8.
35. Horner AA, Raz E. Do microbes influence the pathogenesis of allergic diseases? Building the case for Toll-like receptor ligands. Curr Opin Immunol 2003; 15:614-9.
36. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2002; 2:171-9.
37. Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. Sci Transl Med 2013; 5:192ra85.
38. Bordon J, Aliberti S, Fernandez-Botran R, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013; 17:e76-83.
39. Lee YL, Chen W, Chen LY, et al. Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe communityacquired pneumonia. J Crit Care 2010; 25:176.e7-13.
40. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282:561-8.
41. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995; 107:1342-9.
42. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003; 31: S195-9.
43. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992; 307:97-101.
44. Hallett MB, Lloyds D. Neutrophil priming: the cellular signalings that say 'amber' but not 'green'. Immunol Today 1995; 16:264-8.
45. Sheppard FR, Kelher MR, Moore EE, McLaughlin NJ, Banerjee A, Silliman CC. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. J Leukoc Biol 2005; 78:1025-42.
46. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368:157-69.
47. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 2002; 50:665-72.